Italy formalises gene therapy "ban":
This article was originally published in Clinica
Italy has extended its temporary ban on all forms of gene therapy trials which use retroviral vectors. The Italian health ministry today (October 15 2002) announced that it has passed an urgent order formalising the recent temporary ban (see Clinica No 1028, p 12), until January 31 2003. The order empowers the national healthcare institute (ISS) to approve tests on individual patients, subject to a risk-versus-benefit assessment and the consent of the patient or relevant parties.
You may also be interested in...
UCB's R&D efforts include late-stage diverse but complementary immunologicals and anti-neuroinflammatories.
Janssen and AstraZeneca are among a raft of companies that might this week find out whether the European Medicines Agency will recommend approval of their products for expanded therapeutic indications.
Shares in Iovance Biotherapeutics have soared this week amid reports the US clinical-stage biotechnology company is in active M&A talks.